ClinicalTrials.Veeva

Find clinical trials for Triple Negative Breast Cancer in Madrid, MD

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Breast Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Endometrial Cancer
Non-Small-Cell Lung Carcinoma
Melanoma

Triple Negative Breast Cancer trials near Madrid, MD, ESP:

Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer. (TRIFOUR)

Triple negative breast cancer (TNBC) represents approximately 15% of all breast cancers (BC) wo ...

Enrolling
Triple Negative Breast Cancer
Drug: Nadunolimab
Drug: Carboplatin

Phase 1, Phase 2

Cantargia

Madrid, Spain and 11 other locations

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of trilaciclib versus placebo a...

Active, not recruiting
Breast Cancer
TNBC - Triple-Negative Breast Cancer
Drug: Trilaciclib
Drug: Placebo

Phase 3

G1 Therapeutics

Madrid, Majadahonda, Spain and 70 other locations

This is a two-part open label, non-randomized, Phase 2, study of ZEN003694 in combination with Talazoparib in patients with TNBC without germline mut...

Active, not recruiting
Triple Negative Breast Cancer
Drug: ZEN003694
Drug: Talazoparib

Phase 2

Zenith Epigenetics

Madrid, Spain and 18 other locations

This trial studies ladiratuzumab vedotin (LV) with pembrolizumab in patients with triple-negative breast cancer. -...

Active, not recruiting
Triple Negative Breast Neoplasms
Drug: Pembrolizumab
Drug: ladiratuzumab vedotin

Phase 1, Phase 2

Seagen
Seagen

Madrid, Other, Spain and 49 other locations

with unresectable locally advanced or metastatic PD-L1-positive Triple-Negative Breast Cancer (TNBC) who have not...

Active, not recruiting
Triple-Negative Breast Cancer
Drug: Nab-Paclitaxel
Drug: Atezolizumab

Phase 3

Roche
Roche

Madrid, Spain and 75 other locations

This study will assess the efficacy and safety of Niraparib in participants with either tumor mutation in the BRCA gene (tBRCAmut) HER2- breast...

Active, not recruiting
Neoplasms, Breast
Drug: Niraparib
Drug: Placebo

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Madrid, Spain and 226 other locations

in patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC), refractory to ...

Active, not recruiting
Breast Cancer
Triple Negative Breast Cancer
Drug: Sacituzumab govitecan
Drug: Granulocyte Colony-Stimulating Factor

Phase 2

MedSIR

Madrid, Spain and 9 other locations

the efficacy and safety of atezolizumab plus chemotherapy compared with placebo plus chemotherapy in patients with inoperable recurrent triple...

Active, not recruiting
Triple Negative Breast Neoplasms
Drug: Capecitabine
Drug: Atezolizumab

Phase 3

Roche
Roche

Madrid, Spain and 137 other locations

previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do no...

Enrolling
Triple Negative Breast Cancer
PD-L1 Negative
Drug: Paclitaxel
Drug: Gemcitabine

Phase 3

Gilead Sciences
Gilead Sciences

Madrid, Spain and 502 other locations

with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors ...

Enrolling
Triple Negative Breast Cancer
PD-L1 Positive
Drug: Pembrolizumab
Drug: Paclitaxel

Phase 3

Gilead Sciences
Gilead Sciences

Madrid, Spain and 508 other locations

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems